Establishment Labs Holdings Inc. (ESTA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with record high revenue, positive EBITDA, and increased cash position. The company raised its revenue guidance and expects continued growth in the U.S. and international markets. The Q&A session confirmed positive momentum, strong market share goals, and strategic expansions. Despite some uncertainties, the overall sentiment is very positive, especially with significant growth expectations and strategic initiatives in place. Given the company's small-cap status, a strong positive stock price reaction is anticipated.
Key Financial Performance
Global Revenue $53.8 million in Q3 2025, a 34% increase year-over-year. The growth was driven by meaningful revenue growth in the U.S. and other direct markets.
U.S. Revenue $11.9 million in Q3 2025, up 16% sequentially. This growth is notable as Q3 is typically a seasonally slower quarter for breast procedures, which can decline 20%-30% sequentially.
Gross Profit Margin 70.1% in Q3 2025, a 620 basis point increase from 63.9% in Q3 2024. The improvement is attributed to higher-margin sales in the U.S.
Adjusted EBITDA $1.2 million in Q3 2025, compared to a loss of $8.5 million in Q2 2025 and $12.1 million in Q1 2025. This marks the first positive EBITDA quarter in the company's history, driven by strong sales and higher gross profit in the U.S.
Operating Expenses $41.7 million in Q3 2025, an increase of $2.9 million year-over-year. The increase is due to investments in U.S. commercial operations and the minimally invasive portfolio.
Cash Position $70.6 million at the end of Q3 2025, up from $54.6 million at the end of Q2 2025. The increase was primarily due to drawing the remaining $25 million tranche of the credit facility, offset by operating cash use.
European Direct Market Sales Increased approximately 20% in Q3 2025 compared to Q3 2024, excluding the benefit of currency and the acquisition of the Benelux distributor. This growth reflects the benefits of implemented changes.
Asia-Pacific Sales Rebounded sharply with a sequential growth of 46% in Q3 2025, as expected orders from distributors were realized.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Preserve minimally invasive procedure: Preserve is a breast tissue-preserving procedure that can be done without general anesthesia, offering smaller scars and fast recovery. Surgeons have embraced this new concept, and it has driven category growth and improved economics for surgeons. Early adoption has been positive, with 300 cases performed in the U.S. and growing waitlists.
Flora Tissue Expander: Flora Tissue Expander is now in use at over 150 hospitals in the U.S., supporting the expected launch into breast reconstruction. The company remains on track to file a PMA supplement by the end of the year.
U.S. market growth: The U.S. business is the most important growth segment, with Q3 revenue of $11.9 million, up 16% sequentially. The company expects to achieve a 20% share in the U.S. breast augmentation market by the end of 2025.
International market growth: Direct markets outside the U.S. grew 15% versus last year, with strong performances in Europe, Latin America, and Asia-Pacific. European direct market sales increased approximately 20% this quarter over Q3 2024.
Positive EBITDA: Achieved the first quarter of positive EBITDA in company history with $1.2 million in Q3 2025. The company expects to remain EBITDA positive moving forward.
Gross profit margin: Exceeded 70% gross profit margin for the first time, reaching 70.1% in Q3 2025, driven by higher-margin sales in the U.S.
Market expansion through innovation: The company is leveraging its minimally invasive portfolio, including Preserve and Mia, to expand the breast augmentation market. The portfolio is expected to exceed $30 million globally in 2026.
Surgeon engagement and training: Over 250 surgeons have been trained in Costa Rica since launch, with plans to continue training sessions in 2026. This initiative aims to increase adoption of Motiva implants and Preserve procedures.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company is preparing for U.S. approval in the breast reconstruction segment and filing a PMA supplement by the end of the year. Delays or issues in obtaining these approvals could impact growth plans.
Market Competition: The company faces competitive pressures from legacy brands in the breast augmentation market. Convincing surgeons to offer Motiva implants and patients to choose them over legacy brands is critical for market share growth.
Economic Conditions: Economic uncertainties could impact consumer spending on elective procedures like breast augmentation, potentially affecting revenue growth.
Supply Chain and Tariffs: Goods imported from Costa Rica to the U.S. are subject to duties, which could impact gross margins if not managed effectively.
Cash Flow and Financing: The company aims to reach cash flow positive in 2026 without further equity raises. Any failure to achieve this could necessitate additional financing, impacting financial stability.
Operational Efficiency: The company has made structural changes to manage operating expenses. Inefficiencies or failure to maintain cost controls could impact profitability.
Surgeon Adoption and Training: The success of new procedures like Preserve depends on surgeon adoption and training. Delays or challenges in scaling training programs could hinder market expansion.
Geopolitical and Currency Risks: Sales in international markets are subject to currency fluctuations and geopolitical risks, which could impact revenue and profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: The company has raised its 2025 revenue guidance to exceed $210 million, up from the previous range of $208 million to $212 million. This represents growth of at least 26%.
U.S. Market Growth: The U.S. business is expected to accelerate significantly in Q4 2025, with the company projecting to finish 2025 with an approximate 20% share in the U.S. breast augmentation market. Growth in the breast reconstruction segment is anticipated following expected approval and launch in 2026.
Minimally Invasive Portfolio: The Preserve procedure is expected to drive category growth and improve surgeon economics, with a 40% price premium over standard breast augmentation. The company plans to expand Preserve training sessions in 2026, with two sessions scheduled for Q1 and a similar cadence expected throughout the year. Globally, the minimally invasive portfolio (Mia and Preserve) is projected to exceed $30 million in revenue in 2026.
Gross Margin Improvements: Gross margins are expected to improve by approximately 300 basis points in 2025 compared to 2024, driven by higher-margin U.S. sales.
Cash Flow and Profitability: The company expects to achieve cash flow positive status in 2026 without the need for further equity raises. EBITDA is expected to remain positive moving forward, with meaningful and increasing earnings anticipated in 2027 and beyond.
Global Market Expansion: Revenue growth of more than 20% is expected for several more years, supported by strong performance in direct markets outside the U.S. and increasing adoption of the company's products globally.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the outlook for Q4 and 2025, particularly for O-U.S. trends, new account openings, Preserve uptake, and EBITDA trends?
A:The company expects to exceed $210 million for the year and meaningfully surpass the $40 million previously provided for Q4. The U.S. is the largest market with strong momentum, while O-U.S. markets, particularly in Europe, are seeing over 20% growth in direct markets. EBITDA is expected to continue expanding in Q4 and 2026, with significant leverage still available in the business.
Q:What is the outlook for the international business, particularly in China, and when can reordering be expected?
A:The company has seen stabilization across most O-U.S. markets and strong growth in direct markets, with 20% growth in Europe this quarter. For China, progress is being made with partners, and updates will be provided as the business is built correctly. No specific timeline for reordering was confirmed.
Q:Are you seeing any market weakness in aesthetics, particularly in Q4, as suggested by peers?
A:The company is not seeing market weakness in breast aesthetics and has created significant momentum. Early adopters of Motiva are increasing the number of procedures, and the company expects growth to continue into next year.
Q:Can you provide details on the minimally invasive platforms, including revenue contribution and market development for the $30 million target next year?
A:The company has doubled the number of accounts for Mia this year and is seeing strong performance for Preserve in Europe. The U.S. launch is planned for early next year, with significant demand expected. The company is confident in achieving the $30 million target.
Q:Can you provide more granularity on U.S. sales exceeding $40 million this year?
A:The company expects to significantly exceed $40 million in U.S. sales for Q4, driven by strong momentum and increasing orders. However, as it is the first Q4 in the U.S., there are uncertainties due to holidays and other factors.
Q:What is the preliminary outlook for international market growth next year?
A:The company expects strong performance in international markets, particularly in direct markets, which have been a focus area. Distributor markets also show positive trends. Overall, the company anticipates another year of strong growth in 2026.
Q:What trends are you seeing among U.S. Motiva accounts after adoption?
A:The company is seeing strong growth in U.S. Motiva accounts, with increasing utilization rates and patients specifically requesting Motiva. This momentum is expected to continue into next year, supported by the Preserve launch and small sizes.
Q:Can you clarify the commentary on achieving 20% market share in the U.S. by year-end?
A:The U.S. augmentation market is estimated at $390-$400 million annually. The company expects to achieve a 20% market share as an exit rate by the end of 2025, equating to approximately $20 million in Q4.
Q:How much visibility does the company have for Q4 performance?
A:The company has significant visibility into daily orders and customer metrics, which show strong momentum. However, as it is the first Q4 in the U.S., the company is being prudent in setting expectations.
Q:What is the strategy for U.S. market expansion in 2026?
A:The company plans to expand through increased utilization in existing accounts, adding new accounts, and launching Preserve and small sizes. Additional sales reps will also be hired to support growth. The company remains confident in achieving its 5-year plan of 40%-70% market share in the U.S.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct timeline for reordering in China, citing the need to build the business correctly. Additionally, they did not provide specific details on the exact Q4 U.S. sales figure, citing uncertainties due to holidays and other factors.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Argentina
Benelux
Sales United
States basis
acquisition
adopter
breast procedure
breast reconstruction
cash use
change
choice legacy
doctor
employee
expansion portfolio
group surgeon
improvement
kit
legacy implant
majority
market advantage
market expansion
others
patient choice
practice surgeon
priority
reason
result quarter
sale United
sale distributor
segment
standard
surgeon Costa
surgeon group
surgeon patient
surgeon practice
surgeon training
surgeon woman
survey
use cash
waitlist
ESTA Transcript
Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call reveals strong financial performance with a 25% revenue increase and a significant improvement in gross margin to 70%. The company turned a net loss into a net income, and operating cash flow rose by 50%. These positive financial metrics, coupled with the anticipation of future growth and product launches, suggest a positive sentiment. However, the absence of strategic and operational updates, along with management's caution on risks, tempers expectations slightly. Given the company's small-cap status, the stock is likely to see a positive movement of 2% to 8%.
Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call and Q&A reveal strong growth prospects, particularly in the U.S. market and minimally invasive segment, with raised guidance and strategic expansions. The optimism around Preserve and U.S. market penetration, coupled with improved margins and cash flow projections, supports a positive sentiment. However, some uncertainties in management's responses and lack of specific timelines slightly temper expectations, preventing a 'Strong positive' rating. Given the company's market cap, these factors suggest a likely positive stock movement of 2% to 8% in the short term.
Establishment Labs Holdings Inc. (ESTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Establishment Labs Holdings Inc. (ESTA) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call highlights strong financial performance with record high revenue, positive EBITDA, and increased cash position. The company raised its revenue guidance and expects continued growth in the U.S. and international markets. The Q&A session confirmed positive momentum, strong market share goals, and strategic expansions. Despite some uncertainties, the overall sentiment is very positive, especially with significant growth expectations and strategic initiatives in place. Given the company's small-cap status, a strong positive stock price reaction is anticipated.
ESTA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
